FCGR1A and myeloid sarcoma: In the MS group, there was a non-significant trend to decrease for the following three biomarkers: CD64 granulocytes [MS: mean (SD) 4.1 (1.9); HC: 4.9 (3.1); p value = 0.130; size effect = 0.15], PD-L1 granulocytes [MS: mean (SD) 0.84 (0 (23); HC: 1.02 (0.71); p value = 0.173; size effect = 0.17], and lymphocytes—relative representation (MS: mean (SD) 36.3 (10.3); HC: 32.7 (9.6); p value = 0.072; size effect = 0.18).